Faridoxorubicin

N/A

Report date: 2025/12/18 17:03:46
NME

Base Information

Drug NameFaridoxorubicin
Drug Alias NameAVA6000 pro-DoxorubicinFAP Pro-doxorubicinAVA-6000
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitors
TargetsTopoisomerase IIDNA
Therapy Area/IndicationsSalivary Gland NeoplasmsBreast NeoplasmsCarcinoma, Transitional Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTufts University
China Registration ClassN/A

Develop Information

Active CompaniesAvacta Life Sciences Ltd
Inactive CompaniesN/A
Active IndicationsSalivary Gland NeoplasmsBreast NeoplasmsCarcinoma, Transitional Cell +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A